Kraker, Raymond T.Wallace, David K.Beck, Roy W.Saunders, Christina T.Lorenzi, ElizabethMelia, B. MicheleLi, Zhuokai2024-04-042024-04-042021Kraker RT, Wallace DK, Beck RW, et al. Choice of Dose Level for a Randomized Clinical Trial of Low-Dose Bevacizumab vs Laser for Type 1 Retinopathy of Prematurity. JAMA Ophthalmol. 2021;139(10):1143-1144. doi:10.1001/jamaophthalmol.2021.3192https://hdl.handle.net/1805/39741This study determines which of 8 doses of bevacizumab are effective in treating severe retinopathy of prematurity to carry forward to a large-scale randomized clinical trial.en-USPublisher PolicyAngiogenesis inhibitorsBevacizumabIntravitreal injectionsLaser coagulationRetinopathy of prematurityArticle